文献速递认知障碍与痴呆

临床前阿尔茨海默病中淀粉样蛋白与tau蛋白和认知的关联:纵向研究

Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study.
PubMed 文献 · JAMA Neurol · 2019-01-01

该前瞻性队列研究在哈佛 aging brain 研究中纳入60名临床正常老年人,通过重复Aβ和tau PET及每年认知评估,发现Aβ升高先于tau变化,tau变化与认知下降相关,且Aβ对7年后认知的影响由Aβ和tau的连续变化介导。

要点

  • Aβ升高先于tau沉积增加,tau变化与认知下降显著相关。
  • 进展为轻度认知障碍者tau年增长更高(0.05 SUVr/年)。
  • 初始Aβ对7年后认知的影响由Aβ和tau的序列变化介导。

核心结论

  • 在临床正常老年人中,Aβ升高先于tau沉积增加,tau变化与认知下降相关,且Aβ对远期认知的影响由Aβ和tau的连续变化介导。

研究设计与样本

  • 前瞻性队列研究,2010-2017年于波士顿哈佛 aging brain 研究纳入279名临床正常参与者,本报告分析60名有多次Aβ和tau PET观测者。

主要发现

  • 60名参与者中17名(28%)初始Aβ负荷高,中位年龄73岁(范围65-85)。
  • 序列中介模型显示初始Aβ与7年后认知的关联由Aβ和tau的连续变化介导。

临床怎么用

  • 重复tau-PET可用于追踪疾病进展,重复淀粉样蛋白-PET有助于检测最早期的AD病理变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Positron emission tomography (PET) imaging now allows in vivo visualization of both neuropathologic hallmarks of Alzheimer disease (AD): amyloid-β (Aβ) plaques and tau neurofibrillary tangles. Observing their progressive accumulation in the brains of clinically normal older adults is critically important to understand the pathophysiologic cascade leading to AD and to inform the choice of outcome measures in prevention trials. OBJECTIVE: To assess the associations among Aβ, tau, and cognition, measured during different observation periods for 7 years. DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort study conducted between 2010 and 2017 at the Harvard Aging Brain Study, Boston, Massachusetts. The study enrolled 279 clinically normal participants. An additional 90 individuals were approached but declined the study or did not meet the inclusion criteria. In this report, we analyzed data from 60 participants who had multiple Aβ and tau PET observations available on October 31, 2017. MAIN OUTCOMES AND MEASURES: A median of 3 Pittsburgh compound B-PET (Aβ, 2010-2017) and 2 flortaucipir-PET (tau, 2013-2017) images were collected. We used initial PET and slope data, assessing the rates of change in Aβ and tau, to measure cognitive changes. Cognition was evaluated annually using the Preclinical Alzheimer Cognitive Composite (2010-2017). Annual consensus meetings evaluated progression to mild cognitive impairment. RESULTS: Of the 60 participants, 35 were women (58%) and 25 were men (42%); median age at inclusion was 73 years (range, 65-85 years). Seventeen participants (28%) exhibited an initial high Aβ burden. An antecedent rise in Aβ was associated with subsequent changes in tau (1.07 flortaucipir standardized uptake value ratios [SUVr]/PiB-SUVr; 95% CI, 0.13-3.46; P = .02). Tau changes were associated with cognitive changes (-3.28 z scores/SUVR; 95% CI, -6.67 to -0.91; P = .001), covarying baseline Aβ and tau. Tau changes were greater in the participants who progressed to mild cognitive impairment (n = 6) than in those who did not (n = 11; 0.05 SUVr per year; 95% CI, 0.03-0.07; P = .001). A serial mediation model demonstrated that the association between initial Aβ and final cognition, measured 7 years later, was mediated by successive changes in Aβ and tau. CONCLUSIONS AND RELEVANCE: We identified sequential changes in normal older adults, from Aβ to tau to cognition, after which the participants with high Aβ with greater tau increase met clinical criteria for mild cognitive impairment. These findings highlight the importance of repeated tau-PET observations to track disease progression and the importance of repeated amyloid-PET observations to detect the earliest AD pathologic changes.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Hanseeuw BJ, Betensky RA, Jacobs HIL, et al. Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. JAMA Neurol. 2019. PMID: 31157827. doi:10.1001/jamaneurol.2019.1424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。